Gold is 2025’s best performer. UBS sees more upside
SAN DIEGO—Gerhard Prante, a director at Cibus, Inc. (NASDAQ:CBUS), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Prante sold a total of 2,300 shares of Class A Common Stock over two days, January 15 and 16, 2025. The shares were sold at prices ranging from $2.56 to $2.75 per share, resulting in a total transaction value of $6,106. The transaction comes amid significant stock volatility, with CBUS shares down nearly 86% over the past year. According to InvestingPro data, analyst price targets currently range from $4 to $25, suggesting potential upside from current levels near $2.47.
Following these transactions, Prante now holds 39,907 shares directly. The sales were executed under a pre-arranged trading plan, in accordance with Rule 10b5-1, which Prante adopted on August 16, 2024. InvestingPro's Fair Value analysis suggests CBUS is currently undervalued, with 12 additional exclusive ProTips available to subscribers.
In other recent news, Cibus, Inc., an agriculture chemicals company, has been making significant strides despite facing financial losses. The company recently reported a net loss of $201.5 million, primarily due to an impairment of goodwill. However, Cibus remains optimistic about its future, citing the successful development of its Trait Machine process and partnerships with major seed companies.
Cibus anticipates earning $200 million annually in royalties from rice traits in the U.S. and an additional $150 million from expansion into Asian markets. The company is also planning to launch herbicide-resistant and Pod Shatter Reduction traits, targeting significant market opportunities in the U.S., Latin America, and Asia.
In other developments, the Compensation Committee of Cibus's Board of Directors sanctioned a base salary of $320,000 for Mr. Carlo Broos, a key executive. The company has been experiencing significant revenue growth of over 440% in the last twelve months, though it continues to operate at a loss.
Despite these advancements, Jefferies recently adjusted its price target for Cibus, reducing it to $5.00 from the previous $8.00, while maintaining its Hold rating on the stock. This decision comes as Cibus is noted for carefully managing its balance sheet, focusing on maintaining the quality of its royalty economics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.